VisEn debuts new fluorescent imaging agent
Imaging company VisEn Medical announced last week the launch of its Cat B 750 FAST fluorescent imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.
The agent is being unveiled at this week’s American Heart Scientific Sessions in Orlando, Fla., according to the Bedford, Mass.-based company.
Cathepsin B proteases play a role in disease progression and host response in several disease areas. The Cat B 750 FAST agent is designed to complement in vitro and in vivo protease readouts from cell-based assays and VisEn's existing in vivo agent product lines, providing imaging time points and specificity profiles of cathepsin B within the cathepsin family of proteases, according to the business.
The new Cat B 750 FAST agent represents an additional protease-sensing agent developed from VisEn's new Fluorescent Activatable Sensor Technology (FAST) in vivo agent platform.
The agent is being unveiled at this week’s American Heart Scientific Sessions in Orlando, Fla., according to the Bedford, Mass.-based company.
Cathepsin B proteases play a role in disease progression and host response in several disease areas. The Cat B 750 FAST agent is designed to complement in vitro and in vivo protease readouts from cell-based assays and VisEn's existing in vivo agent product lines, providing imaging time points and specificity profiles of cathepsin B within the cathepsin family of proteases, according to the business.
The new Cat B 750 FAST agent represents an additional protease-sensing agent developed from VisEn's new Fluorescent Activatable Sensor Technology (FAST) in vivo agent platform.